Tyrosine kinase inhibitorFDA-approvedSecond-line
Cobimetinib
How it works
Blocks the MEK pathway, a signaling pathway that drives cancer cell growth, allowing the immune system to attack cancer cells.
Cancer types
Melanoma— BRAF V600E mutation
Efficacy
In clinical trials, around 50% of patients achieved an objective response, with a median progression-free survival of approximately 12.3 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| MEK Inhibitors Show Promise in Treating Resistant Rectal Cancer | Colorectal Cancer | lab-study | — | Source → |
| Testing Treatments for Pancreatic Cancer in Lab Models | Pancreatic Cancer | phase-2 | — | Source → |
| MEK Inhibitor May Help Immune System Fight Triple-Negative Breast Cancer | Breast Cancer | lab-study | — | Source → |
| Combining Alectinib and Cobimetinib to Treat Advanced Lung Cancer | Lung Cancer | phase-1 | — | Source → |
| Cobimetinib for Chronic Myelomonocytic Leukemia with RAS Pathway Mutations | Leukemia | phase-2 | — | Source → |
| Testing a New Combination Therapy for Advanced Ovarian and Endometrial Cancers | Ovarian Cancer | phase-1 | — | Source → |
| Real-world study of melanoma treatment in Germany | Melanoma | observational | Median overall survival was 21.6 months in patients without brain metastases and 7.4 months in patients with brain metastases. | Source → |
| Cobimetinib Plus Vemurafenib Shows Antitumor Activity in Advanced Solid Tumors | Melanoma | phase-2 | The disease control rate was 68% and the objective response rate was 57%. | Source → |
| Switching to Atezolizumab After 3 Months May Not Help Advanced Melanoma Patients | Melanoma | phase-2 | Median progression-free survival was 13.9 months in patients who continued vemurafenib plus cobimetinib, compared to 5.9 months in those who switched to atezolizumab. | Source → |
| Combination Therapy for Metastatic Melanoma Shows Promise | Melanoma | observational | The patient experienced complete remission for 19 months. | Source → |
| Combination Therapy Shows Promise in Advanced Colorectal Cancer | Colorectal Cancer | phase-2 | The disease control rate was 52% (95% CI, 35 to 65), and the objective response rate was 30% (95% CI, 14 to 50). | Source → |
| Researchers Test Combination Therapy for Aggressive Breast Cancer | Breast Cancer | phase-2 | Median progression-free survival was 5.5 months for cobimetinib/paclitaxel versus 3.8 months for placebo/paclitaxel in cohort I. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.